Your browser doesn't support javascript.
loading
Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment.
Grossman, Daniel; Raifman, Sarah; Morris, Natalie; Arena, Andrea; Bachrach, Lela; Beaman, Jessica; Biggs, M Antonia; Hannum, Curtiss; Ho, Stephanie; Schwarz, Eleanor B; Gold, Marji.
Afiliação
  • Grossman D; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, Oakland, CA, United States. Electronic address: Daniel.grossman@ucsf.edu.
  • Raifman S; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, Oakland, CA, United States.
  • Morris N; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, Oakland, CA, United States.
  • Arena A; Department of Family Medicine, Brown University, Pawtucket, RI, United States.
  • Bachrach L; Department of Pediatrics, University of California, San Francisco, CA, United States.
  • Beaman J; Department of Medicine, Division of General Internal Medicine, University of California, Richard Fine People's Clinic, San Francisco, CA, United States.
  • Biggs MA; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, Oakland, CA, United States.
  • Hannum C; Delaware County Women's Center, Chester, PA, United States.
  • Ho S; Highland Hospital, Alameda Health System, Oakland, CA, United States.
  • Schwarz EB; Department of Medicine, Division of General Internal Medicine, Center for Healthcare Policy and Research, University of California, Davis, Sacramento, CA, United States.
  • Gold M; Department of Family and Social Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States.
Contraception ; 107: 36-41, 2022 03.
Article em En | MEDLINE | ID: mdl-34555420
OBJECTIVE(S): To estimate the effectiveness, acceptability, and feasibility of medication abortion with mifepristone dispensed by a mail-order pharmacy after in-person clinical assessment. STUDY DESIGN: This is an interim analysis of an ongoing prospective cohort study conducted at five sites. Clinicians assessed patients in clinic and, if they were eligible for medication abortion and ≤ 63 days' gestation, electronically sent prescriptions for mifepristone 200 mg orally and misoprostol 800 mcg buccally to a mail-order pharmacy, which shipped medications for next-day delivery. Participants completed surveys three and 14 days after enrollment, and we abstracted medical chart data. RESULTS: Between January 2020 and April 2021 we enrolled 240 participants and obtained clinical outcome information for 227 (94.6%); 3 reported not taking either medication. Of those with abortion outcome information (N = 224), 216 (96.4%) completed day-3 and 212 (94.6%) day-14 surveys. Of the 224 that took medications, none reported taking past 70 days' gestation, and complete medication abortion occurred for 217 participants (96.9%, 95% CI 93.7%-98.7%). Most received medications within three days (82.1%, 95% CI 76.5%-86.9%). In the day-3 survey, 95.4% (95% CI 91.7%-97.8%) reported being very (88.4%) or somewhat (6.9%) satisfied with receiving medications by mail. In the day-14 survey, 89.6% (95% CI 84.7%-93.4%) said they would use the mail-order service again if needed. Eleven (4.9%, 95% CI 2.5%-8.6%) experienced adverse events; two were serious (one blood transfusion, one hospitalization), and none were related to mail-order pharmacy dispensing. CONCLUSIONS: Medication abortion with mail-order pharmacy dispensing of mifepristone appears effective, feasible, and acceptable to patients. IMPLICATIONS: The in-person dispensing requirement for mifepristone, codified in the drug's Risk Evaluation and Mitigation Strategy, should be removed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmácia / Misoprostol / Aborto Induzido Tipo de estudo: Observational_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: Contraception Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmácia / Misoprostol / Aborto Induzido Tipo de estudo: Observational_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: Contraception Ano de publicação: 2022 Tipo de documento: Article